Pharmaceutical composition for treating hepatitis B virus (HBV) infection
US6217858A · kind A · utility
0Cited by
2References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 11, 1997 |
| Grant date | Apr 17, 2001 |
| Priority date | — |
| Expiry date | Feb 11, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hepatocytes and other HBV-permissive cells, the active agent being present in sufficient amount to competitively bind to at least one of the sites and thereby to prevent hIL6-mediated HBV infection of hepatocytes and other HBV-permissive cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.